The issue of discovery in an international context is extremely important when our clients are litigating against or for a foreign entity, or a United States company with foreign subsidiaries, parents or affiliates. Key differences exists between discovery rules in the US and in many other countries, and understanding and working within the complexities of those rules can be critical.
Find out how international discovery rules can differ and get an overview of the current approach US courts and lawmakers are taking with respect to discovery issues involving foreign entities. Hear practical pointers from the expert faculty for counseling your clients on strategies for dealing with differing foreign discovery requirements.
What You Will Learn
Topics to be discussed, include:
US Supreme Court Direction
The Hague Convention
FRCP 34 and state analogs
When should defense counsel draw lines
Implications in mass tort and complex litigation
Implications in patent and antitrust litigation
Who Should Attend
Plaintiff and defense counsel interested in the issue of international discovery; in-house counsel with foreign parent or foreign-associated entities or do business outside of the US.
Ellen Relkin, Of Counsel, Weitz & Luxenberg P.C., New York, New York.
Ms. Relkin, whose practice focuses on pharmaceutical and medical device product liability and toxic tort matters, has represented plaintiffs in cases such as: those injured by the birth control patch Ortho Evra, the acne drug Accutane, the oral contraceptives Yaz, Yasmin and Ocella, Hydroxycut dietary supplement products, defective Zimmer Durom Cup hip implants, etc. She is a frequent author and speaker on the topics of scientific evidence.
Ms. Bacon has a broad litigation practice with a focus on pharmaceutical products liability, consumer class actions, and commercial disputes for Fortune 50 companies. She excels at identifying, assessing and implementing legal strategy in line with her clients' core business objectives and has the skills and experience to go to trial and the business sophistication to know when and how to drive the best settlement.
Ms. Fleishman has more than thirty years of courtroom experience to draw upon. A large part of her practice today consists of representing patients who ingested prescription drugs with undisclosed and dangerous side effects, as well as patients who received defective medical devices, were injured by defective products, and individuals who were victims of consumer fraud. She has served in leadership roles in significant Multidistrict Litigation cases in federal and state courts involving pharmaceutical drugs, medical devices, and personal health products.
All Times Eastern
1:30 pm International Discovery: Understanding and Dealing with Foreign Discovery Requirements
2:30 pm Adjournment
This audio program comes to you live on Tuesday, November 13, 2012, via your phone or your computer (your choice). You will be able to email questions to the panel during the program (see below). Materials corresponding to the course may be downloaded or viewed online, though they may not necessarily be followed precisely by the faculty during the program.
• Email your questions before and during the program to email@example.com
Total 60-minute hours of instruction: 1; Total 50-minute hours 1.2. For more information on CLE credits for a particular jurisdiction, click on the “Mandatory CLE Credit” link in the box titled, “Course Details,” at the top left of this web page.
Suggested Prerequisite: Some familiarity with discovery issues arising out of litigation involving foreign entities.
Educational Objective: A better understanding of the rules, regulations, and strategies involved in dealing with discovery issues involving foreign entities